Phase 2 N=165 Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Peptic Ulcer
Primary: Recurrent Peptic Ulcer — 1; 9 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=40 Ulcer Prevention Study in Post Gastric Bypass Patients
Marginal Ulcers
Primary: Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia. — 17; 13 participants
N/A N=455 The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
N/A N=101 Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants With Ulcer Recurrence — 1; 7 participants
N/A N=228 Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
Peptic Ulcer
Primary: Number of Participants With Healed Peptic Ulcer — 106; 101 participants
Phase 4 N=87 Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole
Dyspepsia · Emergency · Pain
Primary: Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment — 17; 19 millimeter — p=0.6
Phase 2 N=247 Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
Phase 4 N=178 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants in Whom Peptic Ulcer Was Healed — 66; 66 participants
N/A N=7 Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
Peptic Ulcer
Primary: Number of Participants Completing Natural Orifice Translumenal Endoscopic Surgical (NOTES) Repair — 2; 1 participants
Phase 4 N=301 Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Stomach Ulcer
Primary: Gastric Ulcer Healing Rate (Number of Subjects Whose Gastric Ulcer Was Healed/Number of Subjects Evaluated x 100) at Week 8 — 70.13; 60.54 percentage of participants
Phase 4 N=123 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
Helicobacter Pylori Infection
Primary: Urea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped. — 1; 3; 1; 0 participants
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
Phase 3 N=519 Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
Gastric Ulcer
Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 7; 22 participants — p=0.005
Phase 3 N=50 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
Gastric Ulcer (GU) · Duodenal Ulcer (DU) · Anastomotic Ulcer (AU)
Primary: Disappearance of Heartburn at Week 8 by Patient Diaries — 2; 0; 0; 1 Participants
Phase 3 N=455 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
Helicobacter Pylori Infection · Dyspepsia
Primary: Number of Participants With Eradication of H. Pylori — 191; 131 Participants — p=0.0001
N/A N=3,183 Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis
Primary: Percentage of Participants With Gastric Ulcer Who Had One or More Adverse Drug Reactions — 1.00 Percentage of Participants
Phase 3 N=311 Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
Stress Ulcer Prophylaxis
Primary: The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase — 2.7; 4.6 % of participants — p=0.393
Phase 3 N=2,426 Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)
Gastric Ulcer · Duodenal Ulcer
Primary: Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s). — 1.35; 1; 6.58 percentage of participants
Phase 3 N=530 A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
Gastric Ulcer
Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg — 10; 23 participants — p=0.020
Phase 3 N=234 Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
Gastric Ulcer
Primary: Percentage of Participants With Endoscopically Confirmed Healing of Gastric Ulcers (GUs) at Weeks 4 or 8 — 91.1; 94.7 percentage of participants
Phase 2 N=102 Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial
Herpangina · Gingivostomatitis · Hand, Foot and Mouth Disease
Primary: Oral Intake in ml/kg — 9.7; 10.7 oral intake in ml/kg
Phase 4 N=232 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 92; 95 participants
Phase 3 N=533 Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
Duodenal Ulcer
Primary: Percentage of Participants With Endoscopically Confirmed Healing of Duodenal Ulcers — 96.9; 96.5 percentage of participants
Phase 3 N=764 A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
Gastrointestinal Hemorrhage
Primary: Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo — 22; 40 Participants
Phase 3 N=119 ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
Dyspepsia · Helicobacter Pylori Infection
Primary: The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing — 59; 1; 7; 36 Participants — p=0.001
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
Phase 3 N=427 Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin
Prevention
Primary: Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis. — 1; 16; 1; 4 Participants — p=<0.001
N/A N=70 Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
Helicobacter Pylori Infection
Primary: Eradication of H Pylori Infection 4 Weeks After Completion of Therapy — 23; 26 participants
N/A N=43 Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
Gastroesophageal Reflux · Laryngopharyngeal Reflux
Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants